AFATINIB FOR CHORDOMA: A phase II, single arm, multi-centre trial evaluating the efficacy of Afatinib as first-line or later-line treatment in metastatic or unresectable chordoma
CGT9486-21-301 – PEAK Trial: A phase 3, randomised, open-label, multicentre clinical study of CGT9486+Sunitinib vs. Sunitinib in subjects with locally advanced, unresectable, or metastatic gastrointestinal stromal tumours
ESPRIT: ESP1/SARC025 Global Collaboration: A phase I study of a combination of the PARP inhibitor, Niraparib and Temozolomide or Irinotecan in patients with previously treated, incurable Ewing sarcoma
ImmunoSARC2: Phase I-II trial of Sunitinib plus Nivolumab after standard treatment in advanced soft tissue and bone sarcomas
